Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Assets Average: 2021-2025

Historic Assets Average for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $686.7 million.

  • Kiniksa Pharmaceuticals International's Assets Average rose 25.12% to $686.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $686.7 million, marking a year-over-year increase of 25.12%. This contributed to the annual value of $553.4 million for FY2024, which is 12.26% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Assets Average of $686.7 million as of Q3 2025, which was up 8.97% from $630.2 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Assets Average high stood at $686.7 million for Q3 2025, and its period low was $220.8 million during Q2 2022.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Assets Average averaged around $543.7 million, with its median value being $531.1 million (2024).
  • Its Assets Average has fluctuated over the past 5 years, first decreased by 25.21% in 2022, then soared by 109.99% in 2023.
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's Assets Average stood at $242.8 million in 2021, then spiked by 89.36% to $459.8 million in 2022, then grew by 9.76% to $504.7 million in 2023, then rose by 12.53% to $567.9 million in 2024, then rose by 25.12% to $686.7 million in 2025.
  • Its Assets Average was $686.7 million in Q3 2025, compared to $630.2 million in Q2 2025 and $589.9 million in Q1 2025.